Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions.

BACKGROUND Point-of-care C-reactive protein (POCCRP) is a biomarker of inflammation that offers clinicians a rapid POC test to guide antibiotic prescribing decisions for acute cough and lower respiratory tract infections (LRTI). However, evidence that POCCRP is cost-effective is limited, particularly outside experimental settings. AIM To assess the cost-effectiveness of POCCRP as a diagnostic tool for acute cough and LRTI from the perspective of the health service. DESIGN AND SETTING Observational study of the presentation, management, and outcomes of patients with acute cough and LRTI in primary care settings in Norway and Sweden. METHOD Using hierarchical regression, data were analysed in terms of the effect on antibiotic use, cost, and patient outcomes (symptom severity after 7 and 14 days, time to recovery, and EQ-5D), while controlling for patient characteristics (self-reported symptom severity, comorbidities, and health-related quality of life) at first attendance. RESULTS POCCRP testing is associated with non-significant positive reductions in antibiotic prescribing (P = 0.078) and increased cost (P = 0.092). Despite the uncertainty, POCCRP testing is also associated with a cost per quality-adjusted life year (QALY) gain of €9391. At a willingness-to-pay threshold of €30,000 per QALY gained, there is a 70% probability of CRP being cost-effective. CONCLUSION POCCRP testing is likely to provide a cost-effective diagnostic intervention both in terms of reducing antibiotic prescribing and in terms of QALYs gained.

[1]  Gardner M. Brown,et al.  Economics of Antibiotic Resistance: A Theory of Optimal Use , 2001 .

[2]  H. Goossens,et al.  Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries , 2009, BMJ : British Medical Journal.

[3]  Kerenza Hood,et al.  Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial , 2009, BMJ : British Medical Journal.

[4]  T. Almdal,et al.  C-reactive protein--can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? , 2006, European journal of internal medicine.

[5]  Jeffrey S Hoch,et al.  Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope , 2006, BMC Health Services Research.

[6]  M Abbott,et al.  Methicillin-resistant Staphylococcus aureus from Europe. , 1992, The Journal of hospital infection.

[7]  N. Ganguly,et al.  Value of serum C-reactive protein concentrations in febrile children without apparent focus. , 1993, Annals of tropical paediatrics.

[8]  J. Coast,et al.  Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? , 1996, Health economics.

[9]  M. Fine,et al.  Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. , 1997, JAMA.

[10]  T Lauritzen,et al.  Near-patient test for C-reactive protein in general practice: assessment of clinical, organizational, and economic outcomes. , 1999, Clinical chemistry.

[11]  M. Christ-Crain,et al.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial , 2004, The Lancet.

[12]  L. Hansson,et al.  Measurement of C-reactive protein and the erythrocyte sedimentation rate in general practice. , 1995, Scandinavian journal of primary health care.

[13]  David Barnett,et al.  Pharmacoeconomics: NICE's approach to decision-making. , 2010, British journal of clinical pharmacology.

[14]  S. le Cessie,et al.  Can history and exam alone reliably predict pneumonia? , 2007, The Journal of family practice.

[15]  B. O'brien,et al.  The death of cost-minimization analysis? , 2001, Health economics.

[16]  Aki Tsuchiya,et al.  A single European currency for EQ-5D health states , 2003, The European Journal of Health Economics, formerly: HEPAC.

[17]  A. Gervaix,et al.  Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. , 2003, Pediatrics.

[18]  A. Briggs,et al.  Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. , 2002, Health economics.

[19]  J. Coast,et al.  Solving the problem of antimicrobial resistance: is a global approach necessary? , 2003, Drug discovery today.

[20]  J. Maselli,et al.  Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. , 2004, The American journal of medicine.

[21]  P. Little,et al.  Validation study of a diary for use in acute lower respiratory tract infection. , 2001, Family practice.

[22]  P. H. Petersen,et al.  Randomised controlled trial of CRP rapid test as a guide to treatment of respiratory infections in general practice. , 2000, Scandinavian journal of primary health care.

[23]  C Bain,et al.  Interpreting the evidence: choosing between randomised and non-randomised studies , 1999, BMJ.

[24]  D. Fuchs,et al.  Value of serum procalcitonin, neopterin, and C-reactive protein in differentiating bacterial from viral etiologies in patients presenting with lower respiratory tract infections. , 2007, Diagnostic microbiology and infectious disease.

[25]  W. Assendelft,et al.  Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review , 2005, BMJ : British Medical Journal.

[26]  R. Hopstaken,et al.  C-reactive protein point of care testing and physician communication skills training for lower respiratory tract infections in general practice: economic evaluation of a cluster randomized trial. , 2011, Journal of evaluation in clinical practice.

[27]  Herman Goossens,et al.  National campaigns to improve antibiotic use , 2006, European Journal of Clinical Pharmacology.

[28]  T. File,et al.  Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. , 2002, The Journal of antimicrobial chemotherapy.

[29]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[30]  R. Hopstaken,et al.  Improving management of patients with acute cough by C-reactive protein point of care testing and communication training (IMPAC3T): study protocol of a cluster randomised controlled trial , 2007, BMC family practice.

[31]  K. Hood,et al.  Influence of CRP testing and clinical findings on antibiotic prescribing in adults presenting with acute cough in primary care , 2010, Scandinavian journal of primary health care.

[32]  Joanna Coast,et al.  Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges , 2011, The European Journal of Health Economics.